Galectin Thera

GALT NASDAQ
4.250
-0.270
-5.97%
Closed 16:00 05/22 EDT
Open
4.520
Prev Close
4.520
High
4.564
Low
4.250
Volume
292.00K
Avg Vol (3M)
383.99K
52 Week High
9.49
52 Week Low
3.170
% Turnover
0.64%
Market Cap
193.78M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers Galectin Thera GALT stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.
MORE >

Recently

Name
Price
%Change